EPHA2 and pancreatic neoplasm: Using this method, the authors identified ephrin type-A receptor 2 (EphA2) as a biomarker for pancreatic cancer EVs and demonstrated that an nPES assay for EphA2-EVs could distinguish pancreatic cancer patients from those with pancreatitis and healthy individuals.